TECH

+ Watchlist + Portfolio

Bio-Techne Corp

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $72.40
52-Week Range: $43.20 – $72.69
Market Cap: $11.38B
P/E (TTM): 62.57
EPS (TTM): 1.16
Dividend Yield: 0.44%

Advanced Metrics

Price/Book: 5.37
PEG Ratio: 2.11
Return on Equity: 9.03%
Return on Assets: 6.67%
Gross Margin: 66.24%
Operating Margin: 27.87%
Profit Margin: 14.97%
Current Ratio: 4.55
Debt/Equity: 0.14
Total Debt: $289.09M
Free Cash Flow: $229.65M
Revenue Growth: 1.30%
Earnings Growth: —
Enterprise Value: $11.38B

TECH Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025	FY2026
Revenue	$1.11B	$1.14B	$1.16B	$1.22B	$1.22B
Cost of Revenue	$349.10M	$366.89M	$389.33M	$429.36M	$415.97M
Gross Profit	$756.50M	$769.82M	$769.73M	$790.27M	$799.07M
Research & Development	$87.14M	$92.49M	$96.66M	$99.50M	$94.77M
Selling, General & Admin	$339.00M	$352.44M	$393.32M	$415.10M	$406.67M
Operating Expenses	$460.67M	$478.82M	$523.32M	$547.47M	$526.46M
Operating Income	$295.83M	$291.00M	$246.40M	$242.80M	$272.61M
EBITDA	$413.76M	$457.11M	$313.14M	$216.88M	$347.67M
Pretax Income	$301.39M	$338.66M	$185.69M	$98.46M	$240.68M
Income Tax	$38.29M	$53.22M	$17.58M	$25.06M	$58.82M
Net Income	$272.05M	$285.26M	$168.10M	$73.40M	$181.86M
Diluted EPS	1.66	1.76	1.05	0.46	1.16
Diluted Shares	164.12M	161.85M	160.77M	159.72M	157.01M

TECH Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025	FY2026
Cash & Equivalents	$172.57M	$180.57M	$151.79M	$162.19M	$264.71M
Receivables	$194.55M	$218.47M	$241.39M	$206.88M	$216.59M
Inventory	$141.12M	$171.64M	$179.73M	$189.45M	$195.74M
Current Assets	$605.56M	$621.48M	$617.42M	$608.30M	$744.40M
Total Assets	$2.29B	$2.64B	$2.70B	$2.56B	$2.59B
Current Liabilities	$176.02M	$128.51M	$159.38M	$175.85M	$163.70M
Long-Term Debt	$243.41M	$350.00M	$319.00M	$346.00M	$200.00M
Total Debt	$325.97M	$454.96M	$419.54M	$444.06M	$289.09M
Total Liabilities	$593.79M	$672.18M	$635.02M	$639.06M	$478.50M
Retained Earnings	$1.12B	$1.31B	$1.33B	$1.07B	$1.14B
Shareholders' Equity	$1.70B	$1.97B	$2.07B	$1.92B	$2.11B
Working Capital	$429.54M	$492.97M	$458.04M	$432.45M	$580.70M
Net Debt	$83.34M	$169.43M	$167.21M	$183.81M	—

TECH Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025	FY2026
Operating Cash Flow	$325.27M	$254.39M	$298.98M	$287.56M	$292.07M
Capital Expenditure	-$44.91M	-$38.24M	-$62.88M	-$31.01M	-$28.85M
Free Cash Flow	$280.36M	$216.15M	$236.10M	$256.55M	$263.22M
Depreciation & Amortisation	$101.07M	$107.24M	$111.71M	$109.90M	$97.36M
Stock-Based Compensation	$42.18M	$39.23M	$38.04M	$40.83M	$41.37M
Investing Cash Flow	-$96.85M	-$265.65M	-$203.03M	-$35.18M	-$18.19M
Financing Cash Flow	-$242.85M	$22.62M	-$122.40M	-$253.91M	-$169.11M
Dividends Paid	-$50.19M	-$50.28M	-$50.42M	-$50.39M	-$49.92M
Share Repurchases	-$160.95M	-$19.56M	-$80.04M	-$275.73M	-$41.67M
Net Change in Cash	-$14.43M	$11.36M	-$26.45M	-$1.53M	$104.77M

TECH Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$316.18M	$316.96M	$286.56M	$295.88M	$311.42M	$321.19M
Cost of Revenue	$101.63M	$118.15M	$98.44M	$104.60M	$103.13M	$109.80M
Gross Profit	$214.56M	$198.81M	$188.11M	$191.28M	$208.29M	$211.39M
Research & Development	$24.58M	$26.03M	$24.24M	$23.13M	$23.45M	$23.95M
Selling, General & Admin	$151.27M	$23.22M	$116.21M	$113.69M	$109.34M	$67.42M
Operating Expenses	$175.85M	$82.12M	$140.45M	$136.82M	$132.79M	$116.40M
Operating Income	$38.71M	$116.69M	$47.66M	$54.46M	$75.50M	$95.00M
EBITDA	$67.85M	$6.43M	$75.27M	$77.66M	$97.80M	$96.94M
Pretax Income	$38.27M	-$22.86M	$47.99M	$50.78M	$71.22M	$70.68M
Income Tax	$15.69M	-$5.18M	$9.81M	$12.78M	$20.18M	$16.06M
Net Income	$22.59M	-$17.68M	$38.19M	$38.01M	$51.05M	$54.62M
Diluted EPS	0.14	-0.11	0.24	0.24	0.32	0.35
Diluted Shares	158.94M	155.76M	156.36M	157.00M	157.40M	157.03M

TECH Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$140.67M	$162.19M	$144.96M	$172.88M	$209.82M	$264.71M
Receivables	$237.14M	$206.88M	$183.90M	$184.61M	$214.56M	$216.59M
Inventory	$191.08M	$189.45M	$203.19M	$205.45M	$201.18M	$195.74M
Current Assets	$627.24M	$608.30M	$609.51M	$637.43M	$688.05M	$744.40M
Total Assets	$2.64B	$2.56B	$2.53B	$2.52B	$2.55B	$2.59B
Current Liabilities	$169.20M	$175.85M	$144.54M	$140.43M	$153.28M	$163.70M
Long-Term Debt	$330.00M	$346.00M	$300.00M	$260.00M	$200.00M	$200.00M
Total Debt	$423.50M	$444.06M	$394.47M	$350.89M	$290.32M	$289.09M
Total Liabilities	$626.23M	$639.06M	$560.33M	$511.71M	$465.30M	$478.50M
Retained Earnings	$1.20B	$1.07B	$1.08B	$1.11B	$1.15B	$1.14B
Shareholders' Equity	$2.02B	$1.92B	$1.97B	$2.01B	$2.09B	$2.11B
Working Capital	$458.04M	$432.45M	$464.96M	$497.01M	$534.77M	$580.70M
Net Debt	$189.33M	$183.81M	$155.04M	$87.12M	—	—

TECH Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$41.12M	$98.20M	$27.59M	$82.41M	$86.66M	$95.42M
Capital Expenditure	-$10.12M	-$4.89M	-$5.36M	-$5.92M	-$9.09M	-$8.48M
Free Cash Flow	$31.00M	$93.31M	$22.22M	$76.49M	$77.58M	$86.94M
Depreciation & Amortisation	$27.57M	$27.11M	$24.34M	$24.71M	$24.17M	$24.14M
Stock-Based Compensation	$11.39M	$4.55M	$11.68M	$13.96M	$10.49M	$5.23M
Investing Cash Flow	-$8.87M	$406.00K	$605.00K	-$5.92M	-$5.82M	-$7.06M
Financing Cash Flow	-$68.05M	-$90.45M	-$44.20M	-$48.99M	-$42.72M	-$33.21M
Dividends Paid	-$12.58M	-$12.39M	-$12.44M	-$12.47M	-$12.52M	-$12.48M
Share Repurchases	-$100.05M	-$100.06M	-$24.00K	$0.00	$0.00	-$41.65M
Net Change in Cash	-$35.80M	$8.15M	-$16.01M	$27.50M	$38.13M	$55.15M

Market Snapshot

About

Bio-Techne Corp. is a global life sciences company that develops and manufactures high-quality reagents, analytical instruments, and diagnostic products for the research and clinical diagnostic markets. The company serves biopharmaceutical, academic, and diagnostic customers worldwide. Bio-Techne operates through two segments: Protein Sciences and Diagnostics and Genomics.